Jaguar Health Inc. Common Stock (JAGX)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, carry little debt, and sell at a sensible price. Jaguar Health fails most of those tests. At the 2026-10-13 close of $4.16, FairStock's calculations show a P/E of -0.01, ROE of -548.83%, ROCE of -38.04%, and a negative 199.8% FCF yield. In fiscal Q2 2026, the quarter ended 2026-06-30, filed revenue was $1.2M and net income was -$12.8M. In fiscal Q1 2026, the quarter ended 2026-03-31, filed revenue was $20.3M and net income was $8.7M, with diluted EPS of -$13.60, an odd mix. For FY2025, revenue was $11.5M and net loss was $53.6M; FY2024 revenue was $11.7M with a net loss of $38.5M. The company has losses in each of the last four years, so the Lynch category is none. Its lead product, Mytesi, may help some patients, but a $3.4M market cap, 47 employees, and tiny revenue do not demonstrate a durable moat. Debt-to-equity of 2.53, Altman Z of -17.43, and Piotroski F-Score of 3/9 point to financial fragility. Trailing free cash flow is -$6.7M, larger than the entire market cap. The 52-week range of $0.31 to $41.53 shows violent speculation. FairStock Score is 14/100. I see no margin of safety. This is a lottery ticket, not a Graham-style bargain.

In plain English: Jaguar Health is a small drug company that sells plant-based medicines for stomach and gut problems in people and animals. It brings in little revenue, loses much more than it earns, and burns through cash faster than its whole market value each year. The stock price does not look cheap against those weak numbers; it looks highly speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer